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Abstract
Cost and outcome estimates based on clinical trial data may not reflect usual clinical practice, yet they are often used to inform 
service provision and budget decisions. To expand understanding of assisted reproduction treatment in clinical practice, an 
economic evaluation of IVF/intracytoplasmic sperm injection (ICSI) data from a single assisted conception unit (ACU) in 
England was performed. A total of 1418 IVF/ICSI cycles undertaken there between October 2001 and January 2006 in 1001 
women were analysed. The overall live birth rate was 22% (95% CI: 19.7−24.2), with the 30- to 34-year age group achieving 
the highest rate (28%). The average recombinant FSH (rFSH) dose/cycle prescribed was 1855 IU. Average cost of rFSH/cycle 
was £646 (SD: £219), and average total cost/cycle was £2932 (SD: £422). Economic data based on clinical trials informing 
current UK guidance assumes higher doses of rFSH dose/cycle (1750–2625 IU), higher average cost of drugs/cycle (£1179), 
and higher average total cost/cycle (£3266). While the outcomes in this study matched UK averages, total cost/cycle was 
lower than those cited in UK guidelines. Utilizing the protocols and (lower) rFSH dosages reported in this study may enable 
other ACU to provide a greater number of IVF/ICSI cycles to patients within given budgets.
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Infertility is a condition estimated to affect one in seven couples 
(14%) in the UK [Human Fertilization and Embryology Authority 
(HFEA), 2008a]. Ovarian stimulation with a follicle stimulating 
hormone (FSH) followed by IVF or intracytoplasmic sperm 
injection (ICSI) is commonly used in assisted reproduction 
treatment.
Uptake of assisted reproduction in the UK appears to be 
increasing; the UK HFEA − the independent regulator 
overseeing safe and appropriate practice in fertility treatment 
and embryo research − reported approximately 42,000 IVF 
cycles undertaken in the UK during 2006–2007 compared with 
34,000 in 1996–1997 (HFEA, 2008b).
The National Institute for Health and Clinical Excellence 
(NICE) is a UK body issuing evidence-based guidelines for 
disease management to the National Health Services (NHS). In 
2004, NICE issued guidelines for assessment and treatment of 
fertility problems (National Collaborating Centre for Women’s 
and Children’s Health, 2004). In the guidelines, which were 
based on clinical trial results and subsequent economic analysis, 
NICE recommended that NHS should fund up to three cycles 
of IVF or ICSI (IVF/ICSI) for most women requiring assisted 
reproduction, finding such treatment to be effective and a cost-
effective use of resources.
While clinical trials are the gold standard for establishing efficacy 
of a treatment, observation and analysis of real-life clinical 
practice also has great value in elucidating the cost and outcomes 
associated with treatments. The objective of the current study 
was to evaluate the utilization, costs and consequences of current 
assisted reproduction practice, particularly with recombinant FSH 
(rFSH), in a real-life clinical setting.
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Materials and methods
The eligible subjects for this study were all the women who 
attended a single assisted conception unit (ACU), serving both 
NHS and private patients in England. The women had received 
IVF/ICSI between 28 October 2001 (the date from which 
electronic data collection was initiated) and 1 December 2006 
(the date the study started). The clinic database enabled us to 
identify the fertility treatments that the women received in 
their treatment cycles whilst preserving anonymity. Assisted 
reproduction cycles eligible for analysis excluded non-IVF/
ICSI treatment (e.g. if intrauterine insemination was used); 
cycles in which frozen embryo replacement was used, as this 
procedure does not involve FSH; and cycles for which rFSH 
prescribing/dispensing data were incomplete or unavailable.
Two sources of drug data were used, prescribed and dispensed. 
The prescribed dose was that written up in the patient notes 
and recorded in the ACU dataset, and the dispensed dose was 
that dispensed by the pharmacy. The pharmacy at the ACU 
manages the dispensing of rFSH closely to minimize wastage 
and keep the cost of the drugs to the hospital and patient as 
low as possible. Normal pharmacy practice is to have the rFSH 
dispensed in two batches, adjusting the second dispensed dose 
if the duration of stimulation is unpredictably prolonged due 
to slow ovarian response. Dosing increases during stimulation 
are rare.
Costing for clinic procedures was based on an internal financial 
audit of the ACU undertaken in 2002–2003. The audit comprised 
a detailed time and motion study and analysis of the majority 
of ACU procedures [i.e. insemination, counselling sessions, 
egg collection, embryo transfer, and embryology preparation, 
consultations (both medical and nursing), blood tests, scans]. 
Samples of each procedure were timed to obtain an average time 
of a stage within the IVF/ICSI procedure. During this process, 
the category of staff employed to undertake the particular stage 
was verified. The stages were medical consultation (new), 
medical consultation (follow-up), counselling session, nurse 
consultation and embryology. Non-staff costs associated with 
a stage [i.e. blood group testing; screening for HIV, hepatitis 
B or C, cystic fibrosis, syphilis; karyotype testing; other blood 
tests; ultrasound scans (baseline and pregnancy); procedure 
preparation; preparation for egg; egg collection; and preparation 
for embryo transfer] were also identified. In this audit, the main 
cost driver of all of the procedures was found to be staff time. 
The audit findings were utilized and assigned unit costs based 
on the medical resource use for the different procedures and 
then calculated an aggregated cost per procedure (Table 1). All 
costs were applied at UK 2007 prices.
It was possible to apply costs to the rFSH (prescribed and 
dispensed) and also apply costs to the other medications 
prescribed for each individual procedure and cycle of treatment 
for each patient. Drug prices were obtained from the British 
National Formulary (BNF, 2007) to ensure that the results could 
be generalized; however, it is important to note that UK hospitals 
often negotiate prices directly with drug companies, and the 
discounts obtained for the various IVF drugs can be substantial.
Rates of clinical pregnancies per cycle, ongoing pregnancies 
per cycle and live births were calculated from the clinic records. 
Using both the procedure and drug costs, it was possible to 
calculate an overall cost per IVF/ICSI procedure for each cycle, 
as well as the average cost per clinical pregnancy, ongoing 
pregnancy and live birth. Using these calculations, the average 
cost per outcome was determined.
During the study period, the women were treated with various 
ovulation stimulation protocols, according to need and ACU 
guidelines at the time. The majority of women received one 
of three protocols: a ‘long’ protocol, which starts with a 
gonadotrophin-releasing hormone (GnRH) analogue on day 
21 to suppress the pituitary (normally a 2-week process); a 
‘short’ protocol, which also uses GnRH analogues, which are 
administered at the start of the cycle; or an antagonist protocol, 
which uses GnRH antagonists for direct pituitary suppression 
(but has a shorter total length of treatment than the long protocol). 
Standard starting doses of rFSH for the three types of protocols 
was 150 IU/day for women under 35 and 200 IU/day for women 
35 and over. The antagonist protocol became a specific focus 
of the comparative analyses, as use of this protocol was the 
exception at the start of the study period, but by the end of the 
study period, it had increased significantly (73% of all cycles 
given at the ACU). For this reason, it was thought it would be of 
interest and relevant to present the findings based on this newer 
protocol alongside those of all protocols combined, in terms of 
mean outcomes, drug utilization and costs.
For completeness, where a cycle was abandoned after initiation 
of treatment, a reduced cost (£1509) was allocated based on full 
costs less costs associated with fertilization and implantation.
Confidence intervals were generated using a non-parametric 
bootstrapping technique (Briggs et al., 1997).
Results
The final study population comprised 1001 women receiving 
1418 treatment cycles. From the 5260 cycles undertaken at 
the ACU during the study period, the following cycles were 
excluded: those in which patients received a gonadotrophin for 
ovarian stimulation other than the rFSH brand Puregon (n = 
20), as the number was too small to make a robust comparison 
between treatments; those in which IVF/ICSI was not received 
(n = 2414) or frozen embryo replacement was used (n = 486); 
those in which IVF was not started or was undertaken at another 
centre (n = 829 cycles); and those for which prescribing and 
dispensing data were missing or incomplete (n = 93).
The mean age of the women contributing to the analysable 
data was 35.9 years (range: 22−49 years), with the greatest 
proportion of patients falling within the 35−39 years of age 
category (Table 2). Where the causes of infertility for each 
cycle were recorded in the analysable database, 33% were 
attributable to male factor and 31% to female factor; 15% were 
unexplained; and 21% had no cause listed or the infertility was 
due to some other cause.
The study compared (using the chi-squared test) the basic 
demographics of the final study dataset of 1418 IVF/ICSI cycles 
used for this analysis and the 232 cycles excluded from the 
analysis because insufficient data were available (e.g. IVF was 
never started or there were missing or incomplete prescribing/338
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Table 2. Demographic and treatment data for women receiving  
IVF/ICSI with pharmacy data (analysable population).
 
  n (%) 
Number of women  1001
Number of cycles  1418 
Age (years) at time of <30   112 (11) 
IVF/ICSI cycles 30−34   259 (26) 
 35−39   384 (38) 
 >40   246 (25) 
Ovarian-stimulation Antagonist   929 (66) 
protocol used Long   169 (12) 
 Short   249 (18) 
 Missing data     61 (4) 
 Other     10 (1)
ICSI = intracytoplasmic sperm injection.
dispensing data). The comparison revealed no differences 
between the two groups with respect to age, which is known to 
be an important predictor for assisted reproduction outcomes. 
Statistically significant differences between the groups were 
found for the cause of infertility, but these were not considered 
clinically significant.
At the end of the study period, the majority of patients attending 
the ACU were receiving rFSH as part of an antagonist ovarian 
stimulation protocol (66%); the long and short protocols 
comprised an additional 30% (Table 2). Mean duration of 
ovarian stimulation for each cycle was 9.1 days (95% CI 
9.0−9.3 days), with oocyte retrieval successfully performed in 
91% of cases. Most frequently, two embryos were transferred.
The clinical pregnancy rate was 36.4% (95% CI 33.9−38.9), the 
ongoing pregnancy rate was 24.4% (95% CI 22.1−26.5), and 
the live birth rate was 22.0% (95% CI 19.7−24.2) (Table 3). 
The cycles excluded (see above) were not statistically different 
from the analysed sample in terms of failure to become pregnant 
or ongoing pregnancy. The influence of age on live birth is 
illustrated in Figure 1, the highest rate of 28% being achieved 
in the 30–34 year age group.
Table 4 summarizes rFSH usage and the cost per cycle per 
pregnancy and live birth. The average prescribed rFSH dose 
per cycle was 1855 IU, while the average dispensed dose 
per cycle was 1891 IU. The average cost of rFSH per cycle 
was £646, and the average cost of concomitant medications 
per cycle was £159. The average cost per cycle for clinic 
procedures was £2127, and the average total cost per cycle 
was £2932. The average costs per clinical pregnancy, ongoing 
pregnancy and live birth were £8058, £12,017 and £13,326 
respectively. Table 5 gives a breakdown of utilization and 
costs per cycle by age group.
Mean outcomes, drug utilization and costs by the most 
commonly used assisted reproduction protocol (i.e. antagonist 
ovarian stimulation) and all protocols combined are shown 
in Table 6. The average total cost of assisted reproduction 
per patient was £2932 overall and £2967 with the antagonist 
protocol and £2874 for the other protocols deployed.
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Table 1. Cost (£ sterling) per procedure. 
Procedure IVF IVF + ICSI FER
Visits and tests 1520 2228   906
Retrieval   212   212 −
Fertilization     53     53 −
Implantation   106   106     95
Total 1891 2599 1001
ICSI = intracytoplasmic sperm injection; FER = frozen embryo replacement.
Table 3. Pregnancy outcome for analysable IVF/ICSI cycles (n = 1418). 
Outcome  n Percentage of total  
   cycles (95% CI)
Pregnancy status Not pregnant 900 63.0
 Missing data     2   0.1
 Clinical pregnancies 516 36.4 (33.9−38.9)
 Ongoing pregnancies 346 24.4 (22.1−26.5)
Pregnancy outcome Live births 312 22.0 (19.7−24.2)
 Not availablea   30   2.1
 Still births     4   0.3
 Ectopic pregnancies   10   0.7
 Miscarriages 155 10.9
 Terminations     5   0.4
CI = confidence interval. 
aPatients lost to follow-up or not having reached their due date at the time of this analysis. 
Note: The difference between the ongoing pregnancy rate and live birth rate is accounted for by the stillbirths  
and patients lost to follow-up or not having reached their due date at the time of this analysis.
Article - Cost and outcome estimates for IVF using rFSH - W Ledger et al.
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Figure 1. Live birth rates by age of woman at time of cycle.
Table 4. Average recombinant FSH (rFSH) usage and cost per  
cycle/pregnancy/live birth.
 
 Mean Standard  
  deviation
Dose prescribed (IU) per cycle   1855 576
Dose dispensed (IU) per cycle   1891 588
Costa per cycle (rFSH)     646 219
Costa per cycle     159 122 
(concomitant medications)
Costa per cycle (procedure costs)b   2127 349
Total costa per cycle   2932 422
Costa per clinical pregnancy   8058  
Costa per ongoing pregnancy 12,017 
Costa per live birth 13,326 
aAll costs in pounds sterling (£). 
bData from financial audit of the ACU undertaken in 2002/2003.
Table 5. Mean recombinant FSH (rFSH) usage and cost per cycle by age group.
 
 Age group (years)   
	 ≤29	 30–34	 35–39	 ≥40
Sample size 150 354 553 361
Dose prescribed (IU) per cycle 1481 1726 1844 2154
Dose dispensed (IU) per cycle 1658 1791 1884 2098
Costa of rFSH   576   611   643   716
Costa per cycle (concomitant medications)   174   160   171   133
Costa per cycle (procedure costs) 2251 2155 2125 2050
Total costa per cycle 3001 2926 2939 2899
aAll costs in pounds sterling (£).
Table 6. Mean outcomes, drug utilization and costs.
 
 Protocol 
 Antagonist All cycles 
 cycles  combineda 
 (n = 929)  (n = 1418)
Clinical pregnancies (%) 39 36
Ongoing pregnancies (%) 27 24
Live births (%) 24 22
Duration of stimulation (days) 9.32 9.14
Total dose prescribed (IU) 1718 1855
Total dose dispensed (IU) 1815 1891
Total cost per assisted reproduction  2967 2932 
cycle (£ sterling) 
aSixty patients with protocol information missing.
Discussion
The real-life costs and outcomes of assisted reproduction for 
women treated at a single ACU in England were assessed. Whilst 
this reflects the case mix and practices at the ACU, interesting 
differences emerged between the present findings and those 
based on clinical trials and the associated economic analyses 
used to inform UK guidance regarding assisted reproduction 
and its reimbursement. For example, that guidance assumes 
that the FSH dose per cycle ranges from 1750 to 2625 IU, the 
cost of drugs per cycle is £1179, and the total cost per cycle of 
IVF/ICSI is £3266 (National Collaborating Centre for Women’s 
and Children’s Health, 2004). These findings are based on 
observational data from a single centre, but one that rigorously 
implemented its treatment protocols and standardized practice 
over the 5-year period from which the data in this study came. 
The findings showed a lower average rFSH dose per cycle 
(1855 IU), a lower average cost of rFSH per cycle (£646), and 
a lower average total cost per cycle of IVF/ICSI (£2932). The 
live birth rate (22%) from the cycles included in this study, 
however, was consistent with the UK average of 21.6% (2005 
data) (HFEA, 2008).
It is reasonable to think that equivalent outcomes to those in 
this ACU are potentially achievable in other, similar ACU. The 
outcomes were achieved with drug utilization and costs below 
those assumed by NICE. It is possible that by substituting rFSH 
as used in the protocols in this ACU’s clinical practice, there 
is the potential to reduce the cost per cycle in other centres. 
The antagonist protocol, with its low-dose rFSH stimulation, 
shorter duration of treatment, fewer side effects, and lower risk 
of ovarian hyperstimulation, may enable other ACU to increase 
the number of fertility treatments within a given budget. This 
study, however, should be replicated in other UK centres to 
ensure that the predicted cost savings are reproducible.
The present findings complement those from a large multicentre 
observational study conducted in Germany (Ludwig et al. 
2004) analysing 54,487 assisted reproduction cycles (37,991 
women) from 74 ACU over a period of 12 months (January to 
December 2002). In that study, the mean ages of patients in the 
rFSH and GnRH groups were 32.6 and 33.4 years respectively, 
and the duration of stimulation was 11.7 days in both groups. 
The live birth rate was 16.9% (3214 live births out of 19,008 
cycles) in the rFSH group compared with 14.5% (837 live 
births out of 5756 cycles) in the GnRH group, the difference 
being statistically significant. Overall, more gonadotrophin 
was required in the GnRH group (2828 IU per cycle) than in 
the rFSH group (2325 IU per cycle). It is of interest to note 
that the mean age of the women included in the analysis (35.9 
years) was somewhat older than in the German study, yet the 
live birth rate was higher (22%). This is an important factor to 
bear in mind when reviewing the results of the analysis, as the 
success rate of IVF diminishes as patient age increases, which 
was evident in the analysis.
Two economic evaluations of assisted reproduction undertaken 
using UK data (Daya et al., 2001; Sykes et al., 2001) report 
favourable cost–effectiveness outcomes for rFSH compared 
with non-recombinant FSH for ovarian stimulation in IVF. 
Two other studies also report favourable cost–effectiveness 
for non-recombinant FSH compared with rFSH (Lloyd et 
al., 2003; Wechowski et al., 2007). All four studies present 
a range of costs for different pregnancy outcomes; however, 
these cost–effectiveness analyses utilize clinical trial data and 
stimulation protocols rather than observational data and may 
not be representative of real life practice.
It was possible to compare the rFSH prescribed and the rFSH 
dispensed. The amounts were consistent and reflect the careful 
control of dispensing by the pharmacy team and the local 
protocols to fine tune dispensing and minimize waste.
The ACU currently utilizes an antagonist protocol with low-
dose FSH stimulation in the majority of cases. The resource 
use and associated costs reported, however, are specific to 
the clinic’s case-mix over the full study period, the shift over 
time toward predominant use of the antagonist protocol and 
the individual selection of patients to receive the different 
stimulation protocols. The long (and ultra-long) protocols in 
this centre are now only used in a minority of cases, namely 
those with severe endometriosis and those with previous 
dyssynchronous follicular response to the antagonist protocol; 
the short protocol is reserved for predicted poor responders and 
women over age 40.
A recent meta-analysis of 22 randomized controlled trials 
involving 3176 patients compared the probability of live 
birth in patients receiving GnRH agonists and GnRH 
antagonists for pituitary suppression (Kolibianakis et al., 
2006). Antagonists and agonists were equally effective in 
achieving a live birth (odds ratio 0.86, 95%, CI 0.72−1.02). 
Subgroup analyses indicated that the result was not affected 
by type of agonist, type of antagonist, type of protocol, or 
type of gonadotrophin used.
The outcomes shown in this study (Table 6) reflect results from 
the full study population and the antagonist-protocol sample. 
Results for the other individual protocols are not presented 
because of the comparatively low proportion of the use of 
the long and short protocol samples and the steady shift of 
preference over time to antagonist protocols, such that it was 
used in nearly 70% of the cycles by the end of the study period. 
This change in case mix should be considered when evaluating 
these results in comparison with those of other ACU.
In addition to the analysis of the cycles of treatment, it would 
have been ideal to present the costs and consequences of 
treatment per patient, incorporating costs and outcomes for any 
frozen embryo replacement (FER) cycles received. This type 
of analysis would have been desirable to further reflect real-
life practice. Unfortunately, the database did not allow us to 
link individual FER cycles with the initial IVF procedures, so 
it was not possible to evaluate and include the extra benefit and 
cost of frozen cycles in this analysis. Despite this, based on the 
clinic audit data, it was possible to make an estimate of £1101 
for the cost of a FER cycle. It would be important to factor the 
impact of incorporating FER cycles into evaluation of assisted 
reproduction in further studies.
The costs used in the analysis are 2007 British National 
Formulary (BNF) prices; however, UK hospitals often negotiate 
directly with drug companies. Discounts negotiated with 
hospitals that have significant buying power are not uncommon, 
and discounts for one or all of the IVF drugs in use can be 
substantial. To ensure that the results for the analysis described 341
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here can be generalized, standard BNF prices for all drugs were 
used.
According to the UK National Infertility Awareness Campaign, 
there continues to be wide variation in the number of cycles 
funded by the government and little progress toward full 
implementation of NICE’s recommendations on infertility 
treatment in the UK (Infertility Network UK, 2008). It is likely 
that cost and access to assisted reproduction contribute to this 
situation. Although caution must be exercised in the interpretation 
of the observational data used for this analysis and the results 
need to be validated in other studies, the present findings 
may represent a step forward in demonstrating that assisted 
reproduction can be both effective and achieved at a lower cost 
than originally predicted by NICE. The UK Government should 
revisit the affordability of funding recommended levels of IVF/
ICSI in light of the better value offered by IVF/ICSI in real-life 
practice, taking efficient drug-delivery practices into account.
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